A randomized, placebo-controlled, double blind, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gem versus gem alone in patients with resected pancreas cancer with activating RAS mutations/survival and immunology analysis of the R1 subgroup.
Peter Muscarella
Research Funding - GlobeImmune
Lalan S. Wilfong
No relevant relationships to disclose
Sharona B. Ross
Consultant or Advisory Role - Covidien; Olympus Medical Systems
Honoraria - Covidien; Olympus Medical Systems
Research Funding - Covidien
Donald A. Richards
No relevant relationships to disclose
Julian Raynov
No relevant relationships to disclose
William E. Fisher
Research Funding - GlobeImmune
Patrick J. Flynn
No relevant relationships to disclose
Samuel H. Whiting
Research Funding - GlobeImmune
Alexander Rosemurgy
Consultant or Advisory Role - Covidien; Olympus Medical Systems
Honoraria - Covidien; Olympus Medical Systems
Research Funding - Covidien; Olympus Medical Systems
Frank E Harrell
Research Funding - GlobeImmune
Nathaniel D. Mercaldo
No relevant relationships to disclose
Scott Kosten
Consultant or Advisory Role - GlobeImmune
John Quiring
Consultant or Advisory Role - GlobeImmune
Sue Speyer
Employment or Leadership Position - GlobeImmune
Joni Richman
Employment or Leadership Position - GlobeImmune
John Ferraro
Employment or Leadership Position - GlobeImmune
Stock Ownership - GlobeImmune
Claire Coeshott
Employment or Leadership Position - GlobeImmune
Allen Cohn
Employment or Leadership Position - GlobeImmune
Timothy C. Rodell
Employment or Leadership Position - GlobeImmune
Stock Ownership - GlobeImmune
Research Funding - GlobeImmune
Other Remuneration - GlobeImmune
David Apelian
Employment or Leadership Position - GlobeImmune
Stock Ownership - GlobeImmune